Related Experiment Video

Updated: Oct 16, 2026

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
11:39

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

Treatment of chronic plaque-stage psoriasis and psoriatic arthritis with mycophenolate mofetil

M Grundmann-Kollmann1, G Mooser, P Schraeder

  • 1Department of Dermatology, Johann Wolfgang Goethe University, Frankfurt/Main, Germany.

Journal of the American Academy of Dermatology
|April 25, 2000
PubMed

Insights

Mycophenolate mofetil (MMF) showed effectiveness in treating psoriatic arthritis but not severe chronic plaque psoriasis. This immunosuppressant was well-tolerated, suggesting potential for psoriatic arthritis patients refractory to other treatments.

Area of Science:

  • Dermatology
  • Immunology
  • Rheumatology

Background:

  • Mycophenolate mofetil (MMF) is an immunosuppressant used in organ transplantation.
  • MMF is increasingly utilized for autoimmune and inflammatory skin conditions.

Purpose of the Study:

  • To evaluate the efficacy and safety of MMF monotherapy in patients with chronic plaque psoriasis and psoriatic arthritis.
  • To assess MMF's response in moderate to severe psoriasis and refractory psoriatic arthritis.

Main Methods:

  • A 10-week study involving 5 patients with chronic plaque psoriasis and 6 with psoriatic arthritis.
  • All patients received MMF monotherapy at a dosage of 2 g/day.
  • Patients had previously shown refractoriness to conventional treatments.

Main Results:

  • MMF was well-tolerated by all participants.
  • Patients with moderate psoriasis and psoriatic arthritis demonstrated improvement.
  • Patients with severe psoriasis did not exhibit a positive response to MMF therapy.

Conclusions:

  • MMF shows promise as a therapeutic option for psoriatic arthritis, particularly in cases resistant to other treatments.
  • MMF's efficacy in severe plaque psoriasis is not supported by this study.
  • MMF is generally safe and effective for blistering autoimmune diseases and pyoderma gangrenosum.

More Related Videos

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain04:50

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain

Published on: May 16, 2025

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
Cryptococcal Meningitis01:27

Cryptococcal Meningitis

Cryptococcal meningitis is a life-threatening opportunistic infection predominantly associated with HIV/AIDS, accounting for over 100,000 deaths annually worldwide. However, it also affects individuals with other forms of immunosuppression, including those undergoing immunosuppressive therapy, organ transplant recipients, patients with innate immunodeficiencies, and individuals with hematological disorders. The infection is caused mainly by Cryptococcus neoformans and Cryptococcus gattii,...
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...